LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses data from LUX-lung 7, a randomised, open-label, phase 2b trial comparing afatinib to gefitinib in the first-line treatment setting with patients who are having epidermal growth factor receptor (EGFR) mutation-positive advanced adenocarcinoma of the lung.

Year of Production:
Running Time:
Color/Sound:

2016
01:30
Color/Sound

Comments are closed.